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Background: Recent data indicated that Natural killer (NK) cells and chemokines could 
play a pivotal role in nasal inflammation. CX3CR1, the only receptor for 
fractalkine/CX3CL1, is abundantly expressed by NK cells, and was recently shown to be 
also a receptor for eotaxin-3/CCL26. However, no reports explored the NK cells-
CX3CL1-CCL26 axis via CX3CR1 in allergy. 
Objective: Our goals were first to determine specifically NK cells recruitment pattern in 
nasal tissue of allergic chronic rhinosinusitis (ACRS) and non-allergic chronic 
rhinosinusitis (NACRS) patients in comparison with healthy controls, and secondly to 
investigate the function of CX3CR1 in NK cell migration.  
Methods Immunohistochemistry, microchemotaxis chambers, flow cytometry and 
confocal microscopy were used in this study. 
Results: Herein, we showed that NK cell infiltrated the epithelial layers of nasal tissue 
only in ACRS patients and not in NACRS patients or controls. NK cells were also more 
numerous in the stroma of the nasal tissue from ACRS patients compared to NACRS 
patients or controls. This migration could be mediated by both CXCL1 and CCL26, since 
these two chemokines induced NK cell migration. Moreover, both molecules stimulated 
also cytoskeleton changes and F-actin reorganization in NK cells. Chemotaxis and 
cytoskeleton changes were sensitive to genistein, a tyrosine kinase inhibitor. By flow 
cytometry, we demonstrated that single antigen nasal provocation challenge increased the 
expression of CX3CR1 on NK cells in allergic rhinitis (AR) patients. The function of this 
receptor was associated by a significant augmentation of NK cells chemotaxis against the 
optimal doses of CX3CL1 and CCL26. 
Conclusion: Our results point out a novel role for CX3CR1 in NK cell migration that 
may contribute to the NK cells trafficking to the allergic upper airway. This could be 
mediated largely by CX3CL1 and CCL26 stimulation of tyrosine kinase pathway. If so, 
then a potent CX3CR1 antagonist would be a suitable therapeutic modality in allergic 
rhinitis and allergic chronic rhinosinusitis. 
 




Chemokines that attract inflammatory cells play a critical role in promoting nasal 
inflammation and the development of nasal polyps. CX3CL1 that belongs to CX3C 
chemokine family is expressed as a membrane bound form and under suitable conditions 
CX3CL1 is cleaved to its soluble form that has been reported to be higher in the plasma 
of patients with AR.  The specific receptor for CX3CL1 is the CX3CR1 that is expressed 
on monocytes, NK cells, T cells and mast cells, mediating adhesion and migration of 
these leukocytes [1-3]. Moreover, segmental allergen challenge up-regulates the function 
of CX3CR1 in peripheral blood CD4 T cells [4]. CX3CL1 protein detection in nasal 
polyps was reported by Danielsen et al [5].  
CC-chemokines are another group of chemokines also implicated in allergic 
inflammation. CCL26 or eotaxin-3 stimulates CCR3 receptors together with eotaxin 1 
and 2. Eotaxin genes are located in the region of chromosome 17q that is linked to atopy 
and total IgE levels [6, 7]. Further, the role of CCL26 in AR and asthma is well reported 
[8-11]. However, recently it has been shown that among eotaxin family only CCL26 has 
the ability to stimulate CX3CR1 receptor and attract not only eosinophils but also NK 
cells [12]. Nonetheless, the function of CX3CR1 in recruiting NK cells to the allergic 
nose via CCL26 is not yet demonstrated.  
Classically NK cells are defined as CD3- CD16+ CD56+ lymphocytes 
subpopulation, but recently NKp46 has been described as a specific marker for the 
detection of both human and mouse NK cells [13]. These cells are mainly found in the 
peripheral blood, but they are also present in tissues, for example in the lung [14]. NK 
cells play a pivotal role in immune response against viruses and tumours by killing 
infected or transformed cells [15, 16].  However, NK cells can also interact with various 
components of the immune system and secrete cytokines and thus regulate or exacerbate 
the immune responses [17, 18].  Some investigators demonstrated the ability of NK cells 
to differentiate in the presence of IL-4 into a cell subset, secreting distinct cytokines 
patterns similar to TH2 profile such as IL-5 and IL-13 [19, 20]. Other studies 
demonstrated the existence of type 2 cytokine-secreting NK cells in AR and showed 
increased number and enhanced cytotoxicity of NK cells [21]. Moreover, we recently 
reported a novel role for NK cells in the pathophysiology of AR by recruiting eosinophils 
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through its IL-8 secretion. This activity is modulated by IL-15 and vitamin D3 [22]. 
Despite of these evidences indicating a role for NK cells in inflammation, little is known 
about NK cells migration in AR and its associated condition, the ACRS. 
  Accordingly, our goal was to investigate NK recruitment in ACRS and in 
NACRS. To determine the mechanism of this migration, the expression of CX3CR1 by 
NK cells after nasal allergen challenge and the NK chemotaxis induced by CX3CL1 and 









Materials and Methods 
Patients and control subjects 
A total of 58 subjects participated in the current study. Out of those, 22 were subjected to 
endoscopic sinus surgery and their nasal biopsies were obtained by trimming of the 
middle turbinate as a part of the surgery. As control group, biopsies from the inferior 
turbinate of patients undergoing partial turbinectomy were obtained (n=5). All biopsies 
were subjected to immunohistochemistry. The 22 patients with chronic rhinosinusitis 
(CRS) with or without nasal polyps were divided into 2 groups: group 1 is formed by11 
patients with non allergic CRS (NACRS, patients who had no history of allergy and was 
proven negative to prick skin tests and allergosorbant test (RAST)) while group 2 is 
formed by 11 patients with allergic CRS (ACRS, patients with long history of poorly 
controlled AR with positive skin tests and RAST to aeroallergens and in whom nasal 
tissue swelling resulted into obstruction of the ostiomeatal complex and the development 
of CRS). The latter was further subdivided into ACRS without asthma (n=6) and ACRS 
with asthma (n=5). The other 31 subjects were 27 allergic (AR) patients who were 
recruited from the rhinology outpatient clinics (patients who are allergic to aeroallergens 
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and who had neither associated sinusitis nor nasal polyps) and 4 healthy volunteers who 
served as control group. These patients contributed to the nasal allergen challenge tests 





Nasal allergen provocation 
AR patients who presented to our rhinology clinics with clinical symptoms of AR and 
were allergic to aeroallergens (house dust mites, grass pollens, fungal spores or animal 
danders) participated in the allergen nasal challenge. The allergen was chosen according 
to the results of skin prick tests and RAST. None of them were taking antihistaminic or 
nasal/systemic cortisone therapy. After obtaining their consent, 10 !l of the diluent were 
introduced into the nose to the anterior part of the inferior turbinate unilaterally on 
impregnated discs. After 15 min and after excluding the nonspecific hyperresponsiveness 
to diluent, nasal lavage with saline was done and then the purified and standardized 
allergen dilution (stallorgenes 100 IR/ml) was introduced into the nose in a similar 
fashion. After 1-2 min the patients were asked to blow their nose and saline nasal 
irrigation was done. Patients’ vital signs were monitored for at least 30 min after 
challenge. The control groups consisted of AR patients who were challenged with the 
diluent solution only.  
 
Cell preparation 
Eosinophils and NK cells were isolated by Percoll (66%) solution separation. Eosinophils 
and NK cells were further purified by negative immunomagnetic cell separation (MACS; 
Miltenyi Biotec, Bergisch Gladbach, Germany).  For eosinophil purification, anti-CD16 
magnetic beads were used for the depletion of neutrophils and NK cells. For NK cells, a 
cocktail of biotin-conjugated antibodies against non NK cells lineage followed by a 
cocktail of magnetic microbeads conjugated to antibodies against biotin were used to 
obtain a population with more than 95% of CD56+ve CD3-ve NK cells (NK Cell 
Isolation Kit-human, Miltenyi Biotec). Both kits were used according to the 
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Chemotaxis assays were performed in triplicate in a 48-well microchemotaxis Boyden 
chamber incubated in 5% CO2 at 37°C for 90 min. Aliquots of 29 µl of the recombinant 
human chemotactic agent CX3CL1 or CCL26 (R&D systems) were placed in the lower 
wells and 50 µl of NK cells suspension (106cells/ml) were placed in the upper wells. The 
two chambers were separated by a 5.0 !m pore polycarbonate membrane (Nuclepore, 
Whatman, Middlesex, UK). Migrated cells adherent to the lower surface were counted in 
5-selected high power fields/well under a light microscope (5 hpf; X400). As for blocking 
experiments the NK cells were pre-treated with 1!M genistein (Sigma), for 60 min at 
370C. Cells were then washed twice, their viability were rechecked by Trypan blue 
staining and was always>98%. Cells were re-suspended in buffer medium and their 
chemotaxis was checked as stated above.  
 
Confocal microscope images 
Thirty !l of cell suspensions at a concentration of 106 cells/ml were placed in 1 µ-Slide  
coated (collagen IV) cell microscopy chamber (Ibidi Integrated BioDiagnostics, Munich-
Germany) and left to adhere for 1h. After two washes, stimulation with buffer, CX3CL1 
or CCL26 was then performed for 5 minutes. Cells were then permeabilized by 0.1% 
saponin buffer (Sigma Aldrich) for 15 min, washed twice and stained with Alexa fluor 
488® – Phalloidin diluted 40X (Invitrogen Molecular probes®) for 1h in the dark, on ice. 
Cells were then washed twice with PBS and analysed by confocal microscopy (Leica 
TCS SP2). As for blocking experiments adhered cells were incubated for 1h with 1 !M 
genistein before being stimulated with CX3CL1 and CCL26.  
 
Flow cytometry 
Staining of PBMC using the following antibodies: CD3-perCP, CD56-PE, CD16-Horizon 
V450, isotype control (BD Biosciences, Erembodegem, Belgium), anti-NKp46-APC 
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(Miltenyi Biotec.) and anti-CX3CR1 FITC (MBL, Woburn, MA USA) were analysed 
with FACS Canto II and Diva software (BD Biosciences). 
 
Immunohistochemistry 
The density of NK cells was assessed by immunohistochemistry in formalin-fixed 
paraffin-embedded nasal tissue biopsies. In order to uncover antigenic sites, antigen 
retrieval was performed by heating 6 min the 4 !m-thick tissue sections in citrate buffer 
(pH 6) at 121°C (pressure cooking). Then the sections were incubated overnight with a 
mouse mAb directed against NKp46/NCR1 (dilution 1/100, clone195314, R&D Systems, 
Oxon, UK). Immunoperoxidase detection was performed using the LSAB2 kit (Dako, 
Glostrup, Denmark). The number of cells stained with the anti-NKp46 antibody was 
counted by an investigator who was blinded to the source of each sample, in 20 adjacent 




Statistical significance was performed by paired t-test and ANOVA. Values of P<0.05 






NK cells recruitment to nasal tissue in CRS 
Surgical nasal biopsies of the middle turbinate of patients undergoing surgery for ACRS 
or NACRS with or without nasal polyps were investigated for the infiltrating numbers of 
NK cells, by immunohistochemistry with antibody against NKp46 (n=22). The results 
were compared to control samples obtained from patients undergoing surgery for 
reduction of inferior turbinates (n=5), who were negative for skin and RAST tests.  
Interestingly, as shown in Fig. 1, patients with ACRS without asthma had strikingly more 
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NKp46+ NK cells infiltrating the nasal tissues than both the NACRS and the control 
groups (Fig. 1C, F-G). An increased number of NK cells in the epithelium were only 
observed in ACRS patients without asthma (Fig. 1F). This infiltration was not observed 
in ACRS patients with asthma (Fig 1E-G). These results indicate a specific recruitment 
pattern of NKp46+ cells to the nasal epithelial layer of patients with ACRS, and that this 
histological feature is lost in ACRS with asthma. 
 
Expression pattern of CX3CR1 by NK cells in AR 
To determine which mechanism could be responsible of this recruitment, we analysed the 
expression of chemokine receptor CX3CR1 on peripheral blood lymphocytes from AR 
patients by flow cytometry. As shown in Fig. 2, CX3CR1 was mostly detected on cells 
expressing NK cell markers such as NKp46 (Fig. 2A), CD56 (Fig. 2B) or CD16 (Fig. 2C) 
and not on T cells (CD3+, Fig. 2D). Moreover, we observed an up-regulation of CX3CR1 
on NK cells after nasal challenge with aeroallergens (Fig. 2E and Table 1), but not in AR 
control group who were challenged with the diluents only (Fig. 2F and Table1). The 
expression of CX3CR1 was not modulated on NK cells from healthy donor challenged 
with histamine (Fig. 2G). Other markers of NK cells such as 2B4 did not show change in 
its expression after nasal challenge (data not shown). Although the number of NK cells 
expressing CX3CR1 increased after nasal allergen challenge in AR patients, the 
percentage of NK cells among the lymphocyte population was not modified by the nasal 
challenge (Table 2). This CX3CR1 up-regulation after aeroallergen challenge suggests a 
modification of NK migration in the pathophysiology of AR. To test this hypothesis, we 
performed chemotaxis experiments. 
 
CX3CL1 and CCL26 induced-NK cells chemotaxis is tyrosine kinase dependent and is 
increased after nasal allergen challenge 
Peripheral blood NK cells from 12 AR patients were tested for their chemotaxis response 
against CX3CL1 and CCL26. As seen in figure 3A and B, both chemokines demonstrated 
a classical bell shape chemotactic dose response, with the optimal activity being at 50 
ng/ml for CX3CL1 (p< 0.05, Fig 3A) and 1!g /ml for CCL26 (p<0.05, Fig 3B). The 
chemotactic activity of the optimal doses of CX3CL1 and CCL26 against NK cells, were 
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blocked when NK cells were pre-treated with a tyrosine kinase inhibitor (genistein, 1!M, 
p <0.0001, Fig. 3C and D). Confocal microscopy studies confirmed that both chemokines 
induced cytoskeletal changes with F-actin reorganization that was sensitive to 1!M 
genistein treatment (Fig. 4).  
To test the impact of CX3CR1 up-regulation after aeroallergens challenge (Fig. 2 
E), we challenged 6 AR patients sensitive to house dust mites (HDM) with HDM 
allergen. NK cell, chemotactic activity against the optimal doses of CX3CL1 and CCL26 
were measured before and 6 hours post challenge. As shown in Fig. 5, 6 hours after 















NK cells recently gained a lot of attention as helper cells in promoting allergic 
inflammation of the airways. The ability of these cells to secrete eosinophilotactic 
mediators provided further insights in the possible cross talk between NK cells and 
eosinophils in promoting allergic inflammation. On other hand, NK could contribute to 
allergen-specific immune suppression (for review [23]). For example, the fact that NK1 
cells inhibit IgE production by B cells [24] and the negative correlation between the 
percentage of NK cells and total IgE levels found in serum of severe atopic dermatitis 
patients [25] suggested a role of NK cells in IgE regulation in these patients. Moreover, a 
10 
 
partial impairment of the NK cell capability of promoting and maintaining appropriate 
TH1 responses has been reported in the blood of respiratory allergic patients [26]. 
To our knowledge, this is the first report that investigating NK cells in nasal mucosa of 
allergic patients. Previously, NK cells have been studied only in the blood or skin of 
allergic patients [21, 26, 27] and in mouse models of asthma (lung and lymph nodes) 
[28]. With a specific marker for NK cells, NKp46 [13], we showed a recruitment of NK 
cells in nasal biopsies of AR patients (Fig. 1). Nothing was reported about the 
mechanisms that recruit NK cells to the allergic nose. Herein, we demonstrate a novel 
functional up-regulation of CX3CR1 on NK cells in AR patients. This results in increased 
migratory response to the competitive agonistic activity of CX3CL1 and CCL26. The 
chemotactic index (CI) of CX3CL1 was almost comparable to CCL26, but the amount of 
CCL26 needed to induce a migration was higher. This is consistent with a recent report 
by Nakayama et al [12] showing that CCL26 is 10 fold less potent than CX3CL1. Since 
these two mediators are well known to be up-regulated in AR, our results provide a 
possible mechanism of NK cell recruitment to the allergic nose, and strongly indicate a 
novel bi-agonistic effect for CCL26 in recruiting both eosinophils and NK cells through 
CCR3 and CX3CR1 receptors, respectively to the allergic inflamed nose.  
Investigation of nasal biopsies from patients undergoing surgery for CRS 
demonstrated a specific recruitment of NK cells in the epithelial layers of the allergic 
nose but not in other non-allergic inflammatory pathologies. An accumulation of NK 
cells was also reported in the superficial dermis and in the epidermis of allergic contact 
dermatitis skin [27]. Interestingly, this histological feature was lost in patients having 
upper airway allergy worsened by asthma. This may be linked to the fact that, in a mouse 
model of self-limited allergic airway inflammation, NK cells were recently implicated in 
the resolution of inflammation [29]. Moreover, attenuation airway hyperresponsiveness 
induced in mice by IL-2 and IL-18 treatment required NK cells [30]. In advanced 
inflammation cascade observed in asthmatic patients NK cells would be less able to 
migrate to the nose, perhaps because they express lower levels of adhesion molecules. 
This is in agreement with the decreased expression of CD54 and CD62L adhesion 
molecules observed on blood NK cells from children with acute exacerbation of asthma 
compared to children with stable asthma after prednisolone therapy [31]. NK cell 
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trafficking in inflamed tissues in mouse model was dependent of CD62L expression [29]. 
Another possible mechanism is the inhibition of NK cells by activin-A [32]. Activin-A 
seems to be a critical regulator of allergic asthma [33] and higher level of activin-A is 
observed in the serum and in bronchial biopsies of asthmatic patients compared to 
controls [33, 34]. Infiltration of NKT cells, another innate cell population, was also 
different in the nasal mucosa of asthmatic and non-asthmatic patients. NKT cells express 
NK markers and an invariant T cell receptor and can also play a role in the pathogenesis 
of asthma (for review [35]). These cells were only detected in the sinus mucosa of 
asthmatic patients and not in non-asthmatic patients [36]. In a mouse model, NKT cells 
played a role in eosinophilic inflammation in acute asthma phase [37].  
  
Migration of NK cells involved chemokine receptor activation [38] and classically 
chemokine signal transduction pathway is mediated by Ca2+ mobilization, protein kinase 
C and heterotrimeric GTP-binding proteins [39], but as alternative pathway kinases and 
phosphatases, adaptor proteins, and a small GTP-binding proteins can be also implicated 
chemokine signalling [37, 39-41]. In this study, genistein, a tyrosine kinase inhibitor, 
abolished cytoskeleton changes and chemotaxis of NK cells suggesting a tyrosine kinase 
signal transduction pathway involved in CX3CR1 stimulation by both CX3CL1 and 
CCL26. This is supported by the fact that NK cell trafficking has been shown to depend 
largely on tyrosine kinase-linked receptors [42].  
In conclusion, our results highlight the role for NK cells recruitment in the 
pathophysiology of AR and point out CX3CR1 as a potential therapeutic target in allergic 
inflammation of the airway. 
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Figure 1: NKp46+ cell infiltration in nasal biopsies. NKp46+ cells (stained in 
brown) in biopsies from (A) control, (B) NACRS and (C) ACRS patients without 
asthma, (D) isotype control on biopsy from NACRS patient. NKp46+ cell 
counting, (E) in nasal biopsies (means ± SEM), (F) in nasal epithelium and (G) in 
subepithelial stroma (bars represent the mean values). Original magnification: A-
D, X200. Control subjects (n=5), NACRS subjects (n=11), CRS subjects without 
asthma (n=6), ACRS subjects with asthma (n=5). NS= not significant. Asterisk 
indicates p<0.0001 and p=0.0236 by paired t-test, for bars 1&3 and bars 3&4, 
respectively. 
 
Figure 2: CX3CR1 expression on NK cells. CX3CR1 FACS staining versus 
NKp46 (A), CD56 (B), CD16 (C) and CD3 (D) staining. CX3CR1 expression on 
NK cells after nasal challenge (E-H) from AR patients challenged with 
aeroallergen (E), challenged with aeroallergen diluent (F) and healthy control 
challenged with histamine (G). 
 
Figure 3: Chemotactic activity of CX3CL1 and eotaxin-3 on human NK cells, 
dose-response experiments. (A) CX3CL1 and (B) CCL26 in inducing NK cell 
chemotaxis. (C&D) Blockade effect of 1!g/ml genistein in NK cell chemotaxis 
against the optimal doses of CX3CL1 and CCL26. Asterisk indicates P<0.05 
(A&B) and p<0.0001 (C&D), by paired t-test & ANOVA. Results are means ± 
SEM of 12 independent experiments performed in triplicate. 
 
Figure 4: Confocal images of NK cell showing shape changes and F-actin 
reorganisation (in green). Results are from one experiment representative of 3, 
(A) stimulation with buffer, (B) stimulation with CX3CL1 and CCL26. Genistein 
treatment alone had no effect on NK cell shape or F-actin (C), but blocked the F-




Figure 5: Effect of nasal allergen challenge with HDM on (A) CX3CL1- and (B) 
CCL26-induced NK cells chemotaxis. Results are means ± SEM of 6 independent 
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